摘要
目的评价合并血脂异常的2型糖尿病患者应用瑞舒伐他汀和阿托伐他汀的短期疗效及安全性。方法 115例2型糖尿病合并血脂异常患者作为研究对象,随机分为瑞舒伐他汀组(57例)及阿托伐他汀组(58例)。瑞舒伐他汀组应用瑞舒伐他汀钙片10 mg/d睡前口服,阿托伐他汀组应用阿托伐他汀钙片20 mg/d睡前口服。比较治疗前后两组患者的血清总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)以及肌酸激酶(CK)指标水平。结果治疗前,两组患者的TC、TG、HDL-C、LDL-C比较,差异均无统计学意义(P>0.05);治疗后瑞舒伐他汀组及阿托伐他汀组患者的TC、TG、LDL-C均低于本组治疗前,差异均具有统计学意义(t=4.947、5.115、8.608、7.718、5.626、8.178,P<0.05);两组患者的HDL-C治疗前后组内比较,差异均无统计学意义(P>0.05);治疗后两组患者的TC、TG、HDL-C、LDL-C组间比较,差异均无统计学意义(P>0.05)。两组患者的ALT、AST、CK水平,组内治疗前后及组间治疗前后比较,差异均无统计学意义(P>0.05)。结论应用瑞舒伐他汀和阿托伐他汀治疗合并血脂异常的2型糖尿病患者,短期内均可有效降低TC、TG及LDL-C水平,同时对转氨酶及肌酸激酶无明显影响,二者均可安全有效地改善2型糖尿病患者的血脂异常。
Objective To evaluate the short-term efficacy and safety of rosuvastatin and atorvastatinfor patients with type2diabetic mellitus and dyslipidemia.Methods A total of115patients with type2diabeticmellitus and dyslipidemia as study subjects were randomly divided into rosuvastatin group(57cases)andatorvastatin group(58cases).The rosuvastatin group had oral rosuvastatin calcium tablet10mg/d before sleeping,and the atorvastatin group had atorvastatin calcium tablet20mg/d before sleeping.Comparison were made onserum total cholesterol(TC),triacylglycerol(TG),low density lipoprotein cholesterol(LDL-C),high densitylipoprotein cholesterol(HDL-C),alanine aminotransferase(ALT),alanine aminotransferase(AST)and creatinekinase(CK)levels before and after treatment in two groups.Results Before treatment,both groups had no statistically significant difference in TC,TG,HDL-C and LDL-C(P>0.05).After treatment,the rosuvastatin groupand atorvastatin group had lower TC,TG and LDL-C than before treatment,and their difference had statisticalsignificance(t=4.947,5.115,8.608,7.718,5.626,8.178,P<0.05).Both groups had no statistically significantdifference in HDL-C before and after treatment(P>0.05).After treatment,both groups had no statisticallysignificant difference in TC,TG,HDL-C and LDL-C(P>0.05).Both groups had no statistically significantdifference in ALT,AST and CK levels of within groups and between two groups before and after treatment(P>0.05).Conclusion For patients with type2diabetic mellitus and dyslipidemia,application of rosuvastatinand atorvastatin both can effectively decrease TC,TG and LDL-C level in short-term,and they have no significanteffect on aminotransferase and creatine kinase at the same time.So both drugs safely and effectively improve thedyslipidemia in patients with type2diabetes.
作者
朱珠
李欣宇
ZHU Zhu;LI Xin-yu(Department of Endocrinology, Dalian Medical University Affiliated Dalian City Central Hospital, Dalian 116033, China)
出处
《中国现代药物应用》
2017年第9期12-14,共3页
Chinese Journal of Modern Drug Application
